Lanreotide Viatris (Lanreotide)

Lanreotide mimics natural somatostatin and binds to somatostatin receptors SSTR2 and SSTR5 on endocrine cells. This binding blocks adenylate cyclase, lowers cyclic AMP, and suppresses the release of growth hormone, insulin, glucagon, and other peptide hormones, thereby controlling disease activity.

The prescribed dose of Lanreotide Viatris is determined by the treating physician based on the individual patient's condition, response, and clinical guidelines. Dosing regimens may vary, and the prescriber will set the appropriate schedule.

Safety data for Lanreotide Viatris in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Lanreotide Viatris, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Lanreotide is similar to other long‑acting somatostatin analogues such as octreotide, offering comparable efficacy in controlling hormone‑driven conditions. Differences may lie in dosing frequency, formulation stability, and specific receptor affinity, which can influence convenience and individual patient response.

Lanreotide Viatris should be stored in a refrigerator at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial to maintain drug stability.

Lanreotide Viatris is administered by subcutaneous injection, typically performed by a healthcare professional. The injection is given into the fatty tissue of the abdomen or thigh, following aseptic technique and the specific schedule prescribed by the clinician.

Serious risks include gallbladder disease such as cholelithiasis, hyperglycaemia or new‑onset diabetes, acute pancreatitis, and severe allergic reactions like anaphylaxis. Patients should be monitored for abdominal pain, changes in blood glucose, and any signs of hypersensitivity.

Lanreotide Viatris is contraindicated in patients with known hypersensitivity to lanreotide or any of its excipients. Caution is advised for individuals with severe hepatic impairment, active gallbladder disease, uncontrolled diabetes, or those who are pregnant or breastfeeding unless clearly indicated by a physician.